Abstract:
The invention relates to compounds of formula (I): in which: R 1 is an alkanoyl group, R 2 is an alkyl group substituted with a group G, or R 1 and R 2 form, together with the nitrogen atom which bears them, an imidazolyl or benzimidazolyl group, substituted with a group G, and G is a -(CH 2 ) n -A-(CH 2 ) m -(CR 4 R 5 ) P -(CH 2 ) O -R 3 group in which n, m, p, o, R 4 , R 5 and A are as defined in the description, and R 3 is a group of formula (II) or formula (III). The invention also relates to the use of said compounds as angiotensin receptor antagonists and as NO donors, in the fields of hypertension and cardiovascular pathologies.
Abstract:
The invention relates to compounds of the formula (I) in which A is an angiotensine-converting enzyme inhibitor including at least one salifiable basic function, B is a compound including at least one acidic sailifiable function and at least one NO-donor group, m is the number of acidic salified functions of B, and n is the number of basic salified functions of A, provided that the bond(s) between A and B are of the ionic type. The invention can be used in drugs.
Abstract:
The invention relates to compounds of the general formula (I) G-(CH2)n-A-(CH2)m-(CR1R2)p-(CH2)o-R3 in which: n is 0, 1, 2 or 3; m is 0, 1, 2 or 3; p is 1 or 0; o is 0, 1 or 2; R1 and R2 each represent a hydrogen atom or an alkyl group; one of the groups -CH2- or -CR1R2- can also be replaced with a phenylene, -PhC(O)- or -PhC(O)O- group; A and G are such as defined in the description; and R3 is a group (II) or (III). The invention can be used for drugs.
Abstract:
The invention relates to compounds of the general formula (I) G-(CH2)n-A-(CH2)m-(CR1R2)p-(CH2)o-R3 in which: n is 0, 1, 2 or 3; m is 0, 1, 2 or 3; p is 1 or 0; o is 0, 1 or 2; R1 and R2 each represent a hydrogen atom or an alkyl group; one of the groups -CH2- or -CR1R2- can also be replaced with a phenylene, -PhC(O)- or -PhC(O)O- group; A and G are such as defined in the description; and R3 is a group (II) or (III). The invention can be used for drugs.
Abstract:
Medicinal products containing the same which are useful in treating or preventing pathologies which are the result of activation of the RhoA/ROCK pathway and phosphorylation of the myosin light chain.
Abstract:
The invention relates to novel isoquinoline derivatives of formula (I), to the synthesis thereof, and to the use of same in the prevention and/or treatment of pathologies resulting from the activation of the RhoA/ROCK pathway and the phosphorylation of the light chain of myosin. X represents a group -C(=0)-, -CH(OH)- or -CH
Abstract:
L'invention concerne de nouveaux dérivés isoquinoléines de formule (I), leur synthèse et leur utilisation dans la prévention et/ou le traitement de pathologies qui résultent de l'activation de la voie RhoA/ROCK et de la phosphorylation de la chaîne légère de la myosine. X représente un groupement -C(=0)-, -CH(OH)- ou -CH2-, et les autres substituants représentent des groupements variés tels que définis dans la revendication 1.
Abstract:
L'invention concerne de nouveaux dérivés isoquinoléines de formule (i), leur synthèse et leur utilisation dans la prévention et/ou le traitement de pathologies qui résultent de l'activation de la voie rhoa/rock et de la phosphorylation de la chaîne légère de la myosine. X représente un groupement -c(=0)-, -ch(oh)- ou -ch